정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 247 | Recruiting | The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load | Polymerase Chain Reaction | Drug: Distilled Water Drug: 1% Povidone Iodine (PVP-I) Drug: 1.5% Hydrogen Peroxide (H2O2) Drug: 0.075% Cetylpyridinium Chloride (CPC) Drug: 0.1% Sodium Hypochlorite |
Phase 4 | King Abdulaziz University | OTHER | 120 | All | 18 Years | Alhamra TETAMMAN clinic (PHC), Jeddah, Saudi Arabia |
| 246 | Enrolling by invitation | The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 | COVID-19 | Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Biological: Placebo |
Phase 3 | Chinese Academy of Medical Sciences | OTHER | 34020 | All | 18 Years | CEMEC Pesquisa Clinica, Sao Bernardo do Campo, Sao Paulo, Brazil Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia |
| 245 | Recruiting | The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin | COVID-19 | Drug: Nitric Oxide lozenges, 30 mg Drug: Placebo |
Phase 2 | Nitric Oxide Innovations LLC | INDUSTRY | 100 | All | 50 Years ~ 85 Years | American Institute of Therapeutics, Lake Bluff, Illinois, United States |
| 244 | Completed | The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol | CoVid 19 Positive | Drug: Hydroxychloroquine, Azithromycin Drug: Hydroxychloroquine, Doxycycline Drug: Hydroxychloroquine, Clindamycin Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose. Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose. Drug: Remdesivir Drug: Tocilizumab Drug: Methylprednisolone Drug: Interferon-Alpha2B Drug: Losartan Drug: Convalescent Serum |
Phase 3 | The Camelot Foundation | OTHER | 1800 | All | FHHI-OI-Camelot; QME, Los Angeles, California, United States | |
| 243 | Terminated | The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention | Corona Virus Disease 19 (Covid 19) | Drug: Colchicine Drug: Standard treatment |
Phase 2 | National and Kapodistrian University of Athens | OTHER | 105 | All | 18 Years | National and Kapodistrian University of Athens, Athens, Greece |
| 242 | Recruiting | The Impact of Camostat Mesilate on COVID-19 Infection | Corona Virus Infection | Drug: Camostat Mesilate Drug: Placebo oral tablet |
Phase 2 | University of Aarhus | OTHER | 580 | All | 18 Years ~ 110 Years | Region Hospital North Jutland, Hjørring, Region Nord, Denmark Department of Infectious Diseases, Aalborg, Denmark Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark Herning Regional Hospital, Herning, Denmark Northzealands hospital - Hillerød, Hillerød, Denmark Horsens Regional Hospital, Horsens, Denmark Bispebjerg hospital, København, Denmark Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark Randers Regional Hospital, Randers, Denmark Silkeborg Hospital, Silkeborg, Denmark Orebro Hsopital, Orebro, Orebrolan, Sweden |
| 241 | Not yet recruiting | The Impact of Fecal Microbiota Transplantation as an Immunomodulation on the Risk Reduction of COVID-19 Disease Progression With Escalating Cytokine Storm and Inflammatory Parameters | Covid19 | Drug: Human fecal microbiota, MBiotix HBI Drug: Placebo Drug: SOC |
Phase 3 | Medical University of Warsaw, Human Biome Institute, Poland | OTHER | 366 | All | 18 Years |